Medincell Stock Consolidates at -2% After a May Boosted by Announcements
The biotech company based in Montpellier continues its decline at midday, in a Parisian market that is also trending downward. This movement occurs as a broker has just raised its price target, reigniting the debate between fundamental momentum and the ongoing technical consolidation.
Portzamparc Raises Target to €30 and Reaffirms Buy Recommendation
On June 3, Portzamparc raised its price target on Medincell from €29.20 to €30.00, while reaffirming its buy recommendation. Based on a price of €26.24, the new target offers a theoretical potential of about 14%. This revision follows a series of significant news for the biotech: the acceptance of the Olanzapine LAI dossier by the EMA on May 22, in partnership with Teva, and the announcement on May 27 of participation in two American biotech conferences in June. Analysts' opinions remain positive, as the stock maintains a 60.2% increase over one year.
The Stock Falls Below its 20-Day Moving Average but Maintains Medium-Term Support
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
At €26.24, the price has fallen below the 20-day moving average (€27.15), a negative gap of 3.35%, indicating that the short-term momentum is waning after surpassing the resistance at €28.72 at the end of May. However, the stock remains above the 50-day moving average at €24.80 (+5.81%) and the 200-day moving average at €25.35 (+3.51%), which keeps the underlying trend intact. The RSI at 53 reflects this pause without extreme signals, in an SBF 120 that is down 0.37% during the session. The next graphical level to watch remains the support at €22.86, a level that marks the consolidation begun since the peak in May.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
